Tranexamic acid use in meningioma surgery – A systematic review and meta-analysis. (April 2023)

• Record Type: Journal Article
• Authors: Clynch, Abigail L.; Gillespie, Conor S.; Richardson, George E.; Mustafa, Mohammad A.; Islim, Abdurrahman I.; Keshwara, Sumirat M.; Bakhsh, Ali; Kumar, Siddhant; Zakaria, Rasheed; Millward, Christopher P.; Mills, Samantha J.; Brodbelt, Andrew R.; Jenkinson, Michael D.
• Is Part Of: Journal of clinical neuroscience. Volume 110(2023)
• Page Start: 53
• Page End: 60
• Publication Date: 2023-04
• Subjects: TXA -- Meningioma -- Blood loss -- Tranexamic acid -- Neurosurgery -- Bleeding; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2023.01.012
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: Tranexamic Acid reduces intraoperative blood loss in meningioma surgery. Tranexamic Acid has no affect on blood transfusion requirement or postoperative outcomes in meningioma surgery. Abstract: Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage. The aim of this review was to evaluate the effect of TXA use on intraoperative and postoperative outcomes of meningioma surgery. A systematic review and meta -analysis was conducted in accordance with the PRISMA statement and registered in PROSPERO (CRD42021292157). Six databases were searched up to November 2021 for phase 2–4 control trials or cohort studies, in the English language, examining TXA use during meningioma surgery. Studies ran outside of dedicated neurosurgical departments or centres were excluded. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Random effects meta -analysis were performed to delineate differences in operative and postoperative outcomes. Four studies (281 patients) were included. TXA use significantly reduced intraoperative blood loss (mean difference 315.7 mls [95% confidence interval [CI] −532.8, −98.5]). Factors not affected by TXA use were transfusion requirement (odds ratio = 0.52; 95% CI 0.27, 0.98), operation time (mean difference = -0.2 h; 95% CI −0.8, 0.4), postoperative seizures (Odds Ratio [OR] = 0.88; 95% CI 0.31, 2.53), hospital stay (mean difference = -1.2; 95% CI −3.4, 0.9) and disability after surgery (OR = 0.50; 95% CI 0.23, 1.06). The key limitations of this review were the small sample size, limited data for secondary outcomes and a lack of standardised method for measuring blood loss. TXA use reduces blood loss in meningioma surgery, but not transfusion requirement or postoperative complications. Larger trials are required to investigate the impact of TXA on patient-reported postoperative outcomes.